--- title: "Weilider Biomedical focuses on in vitro diagnostics and will start bidding on the 4th, with an expected listing on the 24th" type: "News" locale: "en" url: "https://longbridge.com/en/news/226912426.md" description: "Weilide Biomedical focuses on the in vitro diagnostic market and plans to auction 2,808 shares from February 4 to 6, with a starting price of 50 yuan, and is expected to be listed on February 24. The revenue for 2023 is 941 million yuan, with a net profit after tax of 152 million yuan. The revenue for 2024 is expected to be 991 million yuan, a year-on-year increase of 5.36%. The company emphasizes that in vitro testing and preventive medicine are important trends in global health management, and it will deepen the application of digital medical technology to promote stable growth in operations" datetime: "2025-02-03T04:06:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/226912426.md) - [en](https://longbridge.com/en/news/226912426.md) - [zh-HK](https://longbridge.com/zh-HK/news/226912426.md) --- # Weilider Biomedical focuses on in vitro diagnostics and will start bidding on the 4th, with an expected listing on the 24th Weilide Biomedical, which focuses on the in vitro diagnostic market, is conducting a public offering before going public, auctioning off 2,808 shares with a starting bid of NT$50 and a tentative underwriting price of NT$55, expected to be listed on February 24. The auction period for Weilide Biomedical is from February 4 to 6, with bids opening on February 10; public subscription will be conducted from February 12 to 14, and the lottery will take place on February 18. Weilide Biomedical stated in a press release that it benefits from the increasing demand in the preventive medicine market, driving stable growth in operations. In 2023, Weilide Biomedical's revenue is expected to be NT$941 million, with a net profit after tax of NT$152 million, a year-on-year decrease of 0.9%, and earnings per share of NT$3.74; in 2024, revenue is projected to be NT$991 million, a year-on-year increase of 5.36%, with net profit after tax for the first three quarters at NT$130 million, a year-on-year increase of 12.8%, and earnings per share of NT$3.13. Weilide Biomedical pointed out that sales of in vitro diagnostic reagents and equipment are steadily growing, and digital health services have become a key development focus in recent years. In terms of medical information services, Weilide Biomedical has created a digital platform that integrates medical institutions and health data, which can instantly notify physicians of critical test results for patients, and also provides digital management of test data, shortening communication distances in medical testing. Additionally, by optimizing the testing process through the platform, physicians can systematically organize and transmit test prescriptions to testing institutions when issuing them in clinics, improving the efficiency of delivering test medical orders in clinics. The electronic process for submission also reduces manual operation errors and achieves effective record preservation. Weilide Biomedical stated that in vitro testing and preventive medicine have become important trends in global health management, and it is expected to further deepen the application of technology in the digital medical field, combined with in vitro diagnostic business, to promote stable growth in operations ### Related Stocks - [300942.CN](https://longbridge.com/en/quote/300942.CN.md) - [300760.CN](https://longbridge.com/en/quote/300760.CN.md) - [688075.CN](https://longbridge.com/en/quote/688075.CN.md) - [301235.CN](https://longbridge.com/en/quote/301235.CN.md) - [688139.CN](https://longbridge.com/en/quote/688139.CN.md) - [002622.CN](https://longbridge.com/en/quote/002622.CN.md) - [300165.CN](https://longbridge.com/en/quote/300165.CN.md) - [02158.HK](https://longbridge.com/en/quote/02158.HK.md) - [002589.CN](https://longbridge.com/en/quote/002589.CN.md) ## Related News & Research - [Phase 3-ready cancer biotech Parabilis Medicines files for a $100 million IPO](https://longbridge.com/en/news/286972125.md) - [10:39 ETThe SSI Group Appoints Jennifer Strahan as President](https://longbridge.com/en/news/286932678.md) - [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md) - [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md) - [Azafaros Strengthens Leadership Team With Appointment of Amy Sullivan as Chief Financial Officer](https://longbridge.com/en/news/286856224.md)